The global drug eruptions treatment market is expected to be worth US$ 3.89 Billion in the fiscal year 2023, which rose up from US$ 3.66 Billion in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 6.2% CAGR, reaching a value of US$ 7.1 Billion by the end of 2033.
A drug eruption is an unpleasant cutaneous response to a medication. Many medicines, including antimicrobials, NSAIDs, anticonvulsants, sulfa drugs, chemotherapeutic agents, and psychiatric meds, can induce adverse effects. Drug eruption treatment can mimic a range of different skin disorders and should therefore be evaluated in any patient who is taking drugs or has switched medications. Drug eruptions treatment often appears after 2 weeks of starting a new drug or even within days if re-exposure to a specific drug. Scratching is the most prevalent symptom.
Drug eruption treatment occurs in about 2-5% of hospitalized patients and more than 1% of outpatients. Adverse medication responses are more common in women, the elderly, and individuals with impaired immune systems.
The best way to cure a drug rash is to discontinue the medicine that is triggering it. After quitting a medication, it may require 5-10 days for the skin to heal and up to 3 weeks for the rashes to entirely resolve. Oral antihistamine tablets such as hydroxyzine, diphenhydramine, loratadine, fexofenadine, cetirizine, or desloratadine for irritation; topical corticosteroids (cortisone) lotions or creams for red, inflamed skin; and topical antimicrobial ointments for open sores are other options.
| Attributes | Details |
|---|---|
| Expected Market Value (2023) | US$ 3.89 Billion |
| Projected Forecast Value (2033) | US$ 7.1 Billion |
| Global Growth Rate (2023 to 2033) | 6.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global drug eruption treatment market grew at a CAGR of 5.2% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. In most cases, drug eruptions treatment is identified clinically. Skin tests, for example, are performed in laboratories due to their great specificity. Treatment is often beneficial and includes discontinuation of the incorrect drug, indicated treatment, and patient education. For example, people who are allergic to penicillin are recommended to avoid all carbapenems as well as cephalosporins for their own safety. Such factors have been a major driver of this market for drug eruptions treatment.
The global drug eruptions treatment market is being driven by the introduction of innovative treatment approaches, increased knowledge of different drug allergies, and a growth in demand in emerging economies. The development of new medications and intensive continuing research for the prevention of any sort of drug allergy are important to market drivers. The global market for drug eruption treatment is expanding at a modest rate, which is projected to continue over the forecast period.
Such factors are expected to boost the global sales of drug eruptions treatment solutions. As a result, the global drug eruptions treatment market is expected to forecast a CAGR of over 6% from 2023 to 2033.
Various kinds of allergies to different drug types boost the demand
Both over-the-counter and prescription medications have the potential to be the problem. Antibiotics as well as other antimicrobial medications, sulfa medications, nonsteroidal anti-inflammatory medicines (NSAIDs), chemotherapeutic agents, anticonvulsants, biopharmaceuticals, and psychiatric medications are a few examples of common medications that can result in drug eruptions treatment. Examples of common reactions include photodermatitis brought on by topical NSAIDs (like piroxicam) or antibiotics (like minocycline), fixed drug eruptions treatment brought on by acetaminophen or NSAIDs (like Ibuprofen), and the rash that develops after ampicillin in instances of mononucleosis.
The rate of drug eruption treatment associated with several medications is thought to be fewer than 3 per 100 people exposed. Digoxin, aluminum hydroxide, vitamin supplements, bisacodyl, acetaminophen, aspirin, prednisone, thiamine, atropine, hydrochlorothiazide, codeine, morphine, warfarin, insulin, and spironolactone are a few of these. Such factors are sure to propel the market for drug eruptions treatment during the forecast period.
Several treatments for drug eruptions treatment to accelerate the growth
Drug eruptions treatment is being treated with a variety of medications. Desensitization, for instance, is occasionally used to treat drug eruptions treatment, especially when testing is not possible or available. As long as one keeps taking the medication, this method aims to temporarily enable the body to tolerate allergens.
For instance, during penicillin desensitization, progressively greater doses of penicillin are given at intervals until the immune system becomes used to the medication. Such developments are expected to accelerate the demand for drug eruption treatment during the forecast period.
Principal Consultant
High costs and increasing pharmacovigilance impede the global market
During the review period, one of the biggest obstacles facing the worldwide market for drug eruptions treatment may be the high cost linked with them. Additionally, the advancement in drug eruptions treatment calls for highly qualified personnel, which might be one of the biggest obstacles for the global market.
Increasing pharmacovigilance at the same time can help to lessen drug side effects and, as a result, stop any potential eruptions caused by various medications. Thus, such factors can impede the growth of this market and hence curtail the demand for the treatment of drug eruptions treatment.
Rising technological advancements and skin rashes boost the regional demand
North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for drug eruption treatment, with a dominant 7.3% CAGR from 2023 to 2033.
This fast CAGR can be attributed to the increasing number of skin allergy sufferers in the United States of America, improved healthcare facilities, increased research and development in this domain, and cutting-edge technologies. Black Americans suffer mostly from various skin rashes and eruptions due to the various drugs, which lead to eczema and skin inflammation along with hay fever.
In the United States of America, a survey from 2021 found that among people who reported drug eruptions treatment, penicillin and related medicines accounted for 18% of cases. In addition, one in ten persons had an allergy to sulfonamide-containing antibiotics. Hence, there would be a lot of scopes for North American manufacturers to develop in this market during the forecast period.
Increasing treatment options and innovations to propel the sales
During the forecast period, the European market for drug eruptions treatment is expected to garner a steady CAGR of 6.2%. But at the time, the European market for the management of drug eruptions treatment is expected to witness this market gain 27% in 2023.
Drug allergies affect 1% to 2% of hospital admissions and 3% to 5% of outpatients in the United Kingdom, however, it is unknown how common they are in the general population, including children and adults. Hence, the increasing incidence of drug reaction cases has made the European market an attraction for global manufacturers. The presence of the key players in this market has accelerated the revenues for the European market for drug eruptions treatment. Such developments are expected to accelerate the growth in the market from 2023 to 2033.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The antihistamines segment will gain the dominant market share
Over the course of the forecast period, the antihistamine segment by product type is anticipated to occupy a significant share of the global drug eruptions treatment market. In 2023, this category is anticipated to dominate with a 41% revenue share.
Antihistamines may cause unforeseen type B adverse drug events, irrespective of the mechanism, thus it's critical to pay attention to the patient's condition in order to spot such bad reactions. Antihistamines are crucial medications used to treat urticaria and anaphylaxis, but it's vital to remember that antihistamines do have certain risks associated with their usage.
Also, antihistamines can cause bigger lesions on the epidermis, which can further lead to serious conditions. Such factors are expected to accelerate the growth prospects for drug eruptions treatment from 2023 to 2033.
The intravenous segment will demand during the forecast period.
According to the research by Future Market Insights, the intravenous segments will gain popularity during the forecast period. It is anticipated that this segment will occupy a global market share of 25% from 2023 to 2033.
During a case of drug eruptions treatment, most of the time, the symptoms cannot be barred by the oral drugs solely. In such a case, the drug needs to be injected directly into the bloodstream so that they start working quickly. With the IV route of administration, the patients get faster relief from the various allergic reactions within their bodies. These benefits are expected to people the growth of this segment from 2023 to 2033.
The new companies in this market are aimed at developing novel solutions for various kinds of drug eruptions treatment and allergies by curing the symptoms first. Some of the companies are:
Some of the prominent developments of the key players in the market are:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.2% from 2023 to 2033 |
| Market value in 2023 | US$ 3.89 Billion |
| Market value in 2033 | US$ 7.1 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customisation Scope | Available on Request |
The market is forecast to register a CAGR of 6.2% through 2033.
The market is valued to reach US$ 7.1 Billion by 2033.
The global market advanced at a 5.1% HCAGR from 2018 to 2022.
The antihistamines sector is anticipated to grasp a sizable market share of 41%.
A sizeable 25% share pertains to the intravenous category.
The European market to garner a steady CAGR of 6.2%.
1. Executive Summary | Drug Eruptions Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Corticosteroids 5.3.2. Immunosuppressant Drugs 5.3.3. Anti-cytokines 5.3.4. Hemorrheologic Agents 5.3.5. Antihistamines 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Parenteral 6.3.3. Intravenous 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Online Pharmacies 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. Asia Pacific 8.3.5. Middle East & Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.1.4. Singapore 12.2.1.5. Thailand 12.2.1.6. Indonesia 12.2.1.7. Australia 12.2.1.8. New Zealand 12.2.1.9. Rest of Asia Pacific 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. GCC Countries 13.2.1.2. South Africa 13.2.1.3. Israel 13.2.1.4. Rest of MEA 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Key Countries Market Analysis 14.1. USA 14.1.1. Pricing Analysis 14.1.2. Market Share Analysis, 2022 14.1.2.1. By Drug Class 14.1.2.2. By Route of Administration 14.1.2.3. By Distribution Channel 14.2. Canada 14.2.1. Pricing Analysis 14.2.2. Market Share Analysis, 2022 14.2.2.1. By Drug Class 14.2.2.2. By Route of Administration 14.2.2.3. By Distribution Channel 14.3. Brazil 14.3.1. Pricing Analysis 14.3.2. Market Share Analysis, 2022 14.3.2.1. By Drug Class 14.3.2.2. By Route of Administration 14.3.2.3. By Distribution Channel 14.4. Mexico 14.4.1. Pricing Analysis 14.4.2. Market Share Analysis, 2022 14.4.2.1. By Drug Class 14.4.2.2. By Route of Administration 14.4.2.3. By Distribution Channel 14.5. Germany 14.5.1. Pricing Analysis 14.5.2. Market Share Analysis, 2022 14.5.2.1. By Drug Class 14.5.2.2. By Route of Administration 14.5.2.3. By Distribution Channel 14.6. UK 14.6.1. Pricing Analysis 14.6.2. Market Share Analysis, 2022 14.6.2.1. By Drug Class 14.6.2.2. By Route of Administration 14.6.2.3. By Distribution Channel 14.7. France 14.7.1. Pricing Analysis 14.7.2. Market Share Analysis, 2022 14.7.2.1. By Drug Class 14.7.2.2. By Route of Administration 14.7.2.3. By Distribution Channel 14.8. Spain 14.8.1. Pricing Analysis 14.8.2. Market Share Analysis, 2022 14.8.2.1. By Drug Class 14.8.2.2. By Route of Administration 14.8.2.3. By Distribution Channel 14.9. Italy 14.9.1. Pricing Analysis 14.9.2. Market Share Analysis, 2022 14.9.2.1. By Drug Class 14.9.2.2. By Route of Administration 14.9.2.3. By Distribution Channel 14.10. China 14.10.1. Pricing Analysis 14.10.2. Market Share Analysis, 2022 14.10.2.1. By Drug Class 14.10.2.2. By Route of Administration 14.10.2.3. By Distribution Channel 14.11. Japan 14.11.1. Pricing Analysis 14.11.2. Market Share Analysis, 2022 14.11.2.1. By Drug Class 14.11.2.2. By Route of Administration 14.11.2.3. By Distribution Channel 14.12. South Korea 14.12.1. Pricing Analysis 14.12.2. Market Share Analysis, 2022 14.12.2.1. By Drug Class 14.12.2.2. By Route of Administration 14.12.2.3. By Distribution Channel 14.13. Singapore 14.13.1. Pricing Analysis 14.13.2. Market Share Analysis, 2022 14.13.2.1. By Drug Class 14.13.2.2. By Route of Administration 14.13.2.3. By Distribution Channel 14.14. Thailand 14.14.1. Pricing Analysis 14.14.2. Market Share Analysis, 2022 14.14.2.1. By Drug Class 14.14.2.2. By Route of Administration 14.14.2.3. By Distribution Channel 14.15. Indonesia 14.15.1. Pricing Analysis 14.15.2. Market Share Analysis, 2022 14.15.2.1. By Drug Class 14.15.2.2. By Route of Administration 14.15.2.3. By Distribution Channel 14.16. Australia 14.16.1. Pricing Analysis 14.16.2. Market Share Analysis, 2022 14.16.2.1. By Drug Class 14.16.2.2. By Route of Administration 14.16.2.3. By Distribution Channel 14.17. New Zealand 14.17.1. Pricing Analysis 14.17.2. Market Share Analysis, 2022 14.17.2.1. By Drug Class 14.17.2.2. By Route of Administration 14.17.2.3. By Distribution Channel 14.18. GCC Countries 14.18.1. Pricing Analysis 14.18.2. Market Share Analysis, 2022 14.18.2.1. By Drug Class 14.18.2.2. By Route of Administration 14.18.2.3. By Distribution Channel 14.19. South Africa 14.19.1. Pricing Analysis 14.19.2. Market Share Analysis, 2022 14.19.2.1. By Drug Class 14.19.2.2. By Route of Administration 14.19.2.3. By Distribution Channel 14.20. Israel 14.20.1. Pricing Analysis 14.20.2. Market Share Analysis, 2022 14.20.2.1. By Drug Class 14.20.2.2. By Route of Administration 14.20.2.3. By Distribution Channel 15. Market Structure Analysis 15.1. Competition Dashboard 15.2. Competition Benchmarking 15.3. Market Share Analysis of Top Players 15.3.1. By Regional 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 16. Competition Analysis 16.1. Competition Deep Dive 16.1.1. Anuh Pharma Ltd. 16.1.1.1. Overview 16.1.1.2. Product Portfolio 16.1.1.3. Profitability by Market Segments 16.1.1.4. Sales Footprint 16.1.1.5. Strategy Overview 16.1.1.5.1. Marketing Strategy 16.1.2. Avik Pharma 16.1.2.1. Overview 16.1.2.2. Product Portfolio 16.1.2.3. Profitability by Market Segments 16.1.2.4. Sales Footprint 16.1.2.5. Strategy Overview 16.1.2.5.1. Marketing Strategy 16.1.3. Pfizer CentreOne 16.1.3.1. Overview 16.1.3.2. Product Portfolio 16.1.3.3. Profitability by Market Segments 16.1.3.4. Sales Footprint 16.1.3.5. Strategy Overview 16.1.3.5.1. Marketing Strategy 16.1.4. Hovione 16.1.4.1. Overview 16.1.4.2. Product Portfolio 16.1.4.3. Profitability by Market Segments 16.1.4.4. Sales Footprint 16.1.4.5. Strategy Overview 16.1.4.5.1. Marketing Strategy 16.1.5. Bausch Health Companies Inc. 16.1.5.1. Overview 16.1.5.2. Product Portfolio 16.1.5.3. Profitability by Market Segments 16.1.5.4. Sales Footprint 16.1.5.5. Strategy Overview 16.1.5.5.1. Marketing Strategy 16.1.6. APOTEX 16.1.6.1. Overview 16.1.6.2. Product Portfolio 16.1.6.3. Profitability by Market Segments 16.1.6.4. Sales Footprint 16.1.6.5. Strategy Overview 16.1.6.5.1. Marketing Strategy 16.1.7. Astellas Pharma, Inc. 16.1.7.1. Overview 16.1.7.2. Product Portfolio 16.1.7.3. Profitability by Market Segments 16.1.7.4. Sales Footprint 16.1.7.5. Strategy Overview 16.1.7.5.1. Marketing Strategy 16.1.8. Sanofi 16.1.8.1. Overview 16.1.8.2. Product Portfolio 16.1.8.3. Profitability by Market Segments 16.1.8.4. Sales Footprint 16.1.8.5. Strategy Overview 16.1.8.5.1. Marketing Strategy 16.1.9. Novartis AG 16.1.9.1. Overview 16.1.9.2. Product Portfolio 16.1.9.3. Profitability by Market Segments 16.1.9.4. Sales Footprint 16.1.9.5. Strategy Overview 16.1.9.5.1. Marketing Strategy 16.1.10. SBH Sciences 16.1.10.1. Overview 16.1.10.2. Product Portfolio 16.1.10.3. Profitability by Market Segments 16.1.10.4. Sales Footprint 16.1.10.5. Strategy Overview 16.1.10.5.1. Marketing Strategy 17. Assumptions & Acronyms Used 18. Research Methodology
Healthcare
March 2022
REP-GB-14401
March 2023
301 pages
Explore Healthcare Insights
View Reports
Drug Eruptions Treatment Market
